The neuroendocrine phenotype in prostate cancer: basic and clinical aspects

Area of Science:

• Oncology
• Urology
• Cell Biology

Background:

• Prostate adenocarcinomas often show neuroendocrine (NE) differentiation.
• The clinical significance of NE differentiation in prostate cancer is under investigation.
• NE phenotype is increasingly recognized as a factor in prostate cancer prognosis and progression.

Purpose of the Study:

• To explore the role of NE differentiation in prostate cancer progression, particularly during androgen-suppression therapy.
• To identify mechanisms by which NE cells influence prostate cancer growth and survival.
• To investigate the dynamic nature of NE differentiation in response to therapy.

Main Methods:

• Immunohistochemistry to detect NE markers.
• Analysis of NE cell markers (e.g., chromogranin A) in tissue and circulation.
• Review of pre-clinical and clinical studies on androgen-suppression therapy and NE differentiation.

Main Results:

• NE cells are androgen receptor-negative, enabling survival during androgen deprivation.
• NE cells secrete factors that promote proliferation, inhibit apoptosis, and stimulate angiogenesis in adjacent cancer cells.
• Androgen-suppression therapy directly stimulates NE differentiation, increasing NE marker expression.
• Chromogranin A (CgA) is a sensitive marker for NE phenotype and elevated plasma CgA correlates with poor prognosis in hormone-refractory disease.

Conclusions:

• NE differentiation is a dynamic process in prostate cancer, exacerbated by androgen-suppression therapy.
• NE cells play a significant role in prostate cancer progression and resistance to therapy.
• CgA is a valuable biomarker for assessing NE differentiation and prognosis in advanced prostate cancer.